Category: Uncategorized
-
Orbit Genomics Named As Finalist In 2024 Pepperdine Most Fundable Companies Competition
Orbit Genomics, Inc. has been named one of the 30 finalists for the Pepperdine Most Fundable Companies Competition, chosen from over 2,300 applicants. We would like to thank Pepperdine and the judges for this competition in recognizing the company for its efforts in developing highly accurate genomics tests for oncology, cardiovascular, longevity and other indications.…
-
Orbit Genomics, Inc. was awarded a two-year, $2million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer blood test
Orbit Genomics was awarded a two-year $2MM Direct to Phase II SBIR Grant from NIH/NCI to develop the second-generation of our lung cancer test, OrbiSeq-L. OrbiSeq-L, is a simple blood test that diagnoses lung cancer in patients that have low-dose CT scans with indeterminate pulmonary nodules, IPNs. Every year, 2.5-3 million Americans have low-dose CT…
-
AI-based Medical Device Company Imidex and Orbit Genomics Form Strategic Relationship to Explore the Detection of Lung Cancer in Early Stages
https://www.prnewswire.com/news-releases/ai-based-medical-device-company-imidex-and-precision-genomix-company-orbit-genomics-form-strategic-relationship-to-explore-the-detection-of-lung-cancer-in-early-stages-302229700.html?tc=eml_cleartime
-
Orbit Genomics Celebrates Graduation From The Cancer X Accelerator Program
Orbit Genomics is proud to attend the graduation of the CancerX Accelerator’s inaugural cohort. We were selected from over 100 startup applicants to participate in this year’s program which included months of mentorship, hands-on learning at the Moffit Cancer Center, and many professional sessions with Champions. We look forward to continue strengthening the relationships with…
-
Orbit Genomics Has Been Selected For The Inaugural Cohort of Startups In CancerX’s Accelerator Program
We are thrilled to announce that Orbit Genomics has been selected for the inaugural cohort of startups in CancerX’s Accelerator program! CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot. A team of Accelerator Champions…
-
Orbit Genomics Named A Deep Tech Pioneer By Hello Tomorrow
We’re thrilled to announce we’ve been named a Deep Tech Pioneer by Hello Tomorrow! Out of an astonishing 4,500 applications from 120 countries, Orbit Genomics stood out as one of the most promising in the realm of deep tech. Come and meet us at the Hello Tomorrow Global Summit in March 2024, the cornerstone event…
-
Orbit Genomics Partners With Icahn School of Medicine at Mount Sinai
We are thrilled to announce that Orbit Genomics has partnered with the esteemed Icahn School of Medicine at Mount Sinai for optimization of our revolutionary lung cancer diagnostic platform. This collaboration will allow us to further advance the accuracy and reliability of our test, which will have significant implications for the future of cancer diagnosis…
-
Orbit Genomics Raises $3 million To Launch Its Lung Cancer Diagnostic Test.
https://www.einpresswire.com/article/559943576/orbit-genomics-raises-3-million-to-launch-a-lung-cancer-diagnostic-test
-
Orbit Genomics was awarded a $250,000 Early Stage Capital and Retention Grant as part of Colorado Office of Economic Development and International Trade (OEDIT)’s Advanced Industries Accelerator Grant Program
https://oedit.colorado.gov/press-release/86-million-advanced-industries-awards-accelerate-36-colorado-start-ups
-
Orbit Genomics is thrilled to be part of 18 companies selected from more than 850 applicants for to Plug and Play’s Health Batch 9
https://www.prnewswire.com/news-releases/plug-and-play-accepts-130-startups-for-their-winter-2019-batches-300925759.html?tc=eml_cleartime